156 related articles for article (PubMed ID: 23220071)
1. Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
Heinen S; Pluthero FG; van Eimeren VF; Quaggin SE; Licht C
Mol Immunol; 2013 May; 54(1):84-8. PubMed ID: 23220071
[TBL] [Abstract][Full Text] [Related]
2. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
[TBL] [Abstract][Full Text] [Related]
4. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
Rigothier C; Delmas Y; Roumenina LT; Contin-Bordes C; Lepreux S; Bridoux F; Goujon JM; Bachelet T; Touchard G; Frémeaux-Bacchi V; Combe C
Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
Gediz F; Payzin BK; Ecemis S; Güler N; Yilmaz AF; Topcugil F; Berdeli A
Transfus Apher Sci; 2016 Dec; 55(3):357-362. PubMed ID: 27742267
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.
Davin JC; Gracchi V; Bouts A; Groothoff J; Strain L; Goodship T
Am J Kidney Dis; 2010 Apr; 55(4):708-11. PubMed ID: 19854549
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W
Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
[TBL] [Abstract][Full Text] [Related]
8. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
Fakhouri F; Frémeaux-Bacchi V; Loirat C
Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
[TBL] [Abstract][Full Text] [Related]
9. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation.
Tran H; Chaudhuri A; Concepcion W; Grimm PC
Pediatr Nephrol; 2014 Mar; 29(3):477-80. PubMed ID: 24221349
[TBL] [Abstract][Full Text] [Related]
10. Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options.
De S; Waters AM; Segal AO; Trautmann A; Harvey EA; Licht C
Pediatr Nephrol; 2010 Jan; 25(1):97-104. PubMed ID: 19856002
[TBL] [Abstract][Full Text] [Related]
11. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
Hirt-Minkowski P; Dickenmann M; Schifferli JA
Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
[TBL] [Abstract][Full Text] [Related]
12. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.
Mache CJ; Acham-Roschitz B; Frémeaux-Bacchi V; Kirschfink M; Zipfel PF; Roedl S; Vester U; Ring E
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1312-6. PubMed ID: 19556379
[TBL] [Abstract][Full Text] [Related]
13. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
Sengul Samanci N; Ayer M; Ergen A; Ozturk S
Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
[TBL] [Abstract][Full Text] [Related]
14. Clinical grand rounds: atypical hemolytic uremic syndrome.
Hodgkins KS; Bobrowski AE; Lane JC; Langman CB
Am J Nephrol; 2012; 35(5):394-400. PubMed ID: 22517061
[TBL] [Abstract][Full Text] [Related]
15. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
[TBL] [Abstract][Full Text] [Related]
16. First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis.
Szarvas N; Szilágyi Á; Tasic V; Nushi-Stavileci V; Sofijanova A; Gucev Z; Szabó M; Szabó A; Szeifert L; Reusz G; Rusai K; Arbeiter K; Müller T; Prohászka Z
Ital J Pediatr; 2014 Dec; 40():101. PubMed ID: 25496981
[TBL] [Abstract][Full Text] [Related]
17. Hemolytic Uremic Syndrome in Pregnancy and Postpartum.
Bruel A; Kavanagh D; Noris M; Delmas Y; Wong EKS; Bresin E; Provôt F; Brocklebank V; Mele C; Remuzzi G; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1237-1247. PubMed ID: 28596415
[TBL] [Abstract][Full Text] [Related]
18. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report.
Giordano M; Castellano G; Messina G; Divella C; Bellantuono R; Puteo F; Colella V; Depalo T; Gesualdo L
Pediatrics; 2012 Nov; 130(5):e1385-8. PubMed ID: 23027168
[TBL] [Abstract][Full Text] [Related]
19. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab.
Besbas N; Gulhan B; Karpman D; Topaloglu R; Duzova A; Korkmaz E; Ozaltin F
Pediatr Nephrol; 2013 Jan; 28(1):155-8. PubMed ID: 22956028
[TBL] [Abstract][Full Text] [Related]
20. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.
Noris M; Remuzzi G
Curr Opin Nephrol Hypertens; 2013 Nov; 22(6):704-12. PubMed ID: 24076560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
